Standard
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. / Høgdall, Claus; Fung, Eric T; Christensen, Ib J; Nedergaard, Lotte; Engelholm, Svend A; Petri, Anette L; Risum, Signe; Lundvall, Lene; Yip, Christine; Pedersen, Anette T; Hartwell, Dorthe; Lomas, Lee; Høgdall, Estrid V S.
In:
Gynecologic Oncology, Vol. 123, No. 2, 2011, p. 308-13.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Høgdall, C, Fung, ET, Christensen, IJ, Nedergaard, L, Engelholm, SA, Petri, AL, Risum, S, Lundvall, L, Yip, C
, Pedersen, AT, Hartwell, D, Lomas, L & Høgdall, EVS 2011, '
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer',
Gynecologic Oncology, vol. 123, no. 2, pp. 308-13.
https://doi.org/10.1016/j.ygyno.2011.07.018
APA
Høgdall, C., Fung, E. T., Christensen, I. J., Nedergaard, L., Engelholm, S. A., Petri, A. L., Risum, S., Lundvall, L., Yip, C.
, Pedersen, A. T., Hartwell, D., Lomas, L., & Høgdall, E. V. S. (2011).
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Gynecologic Oncology,
123(2), 308-13.
https://doi.org/10.1016/j.ygyno.2011.07.018
Vancouver
Høgdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL et al.
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Gynecologic Oncology. 2011;123(2):308-13.
https://doi.org/10.1016/j.ygyno.2011.07.018
Author
Høgdall, Claus ; Fung, Eric T ; Christensen, Ib J ; Nedergaard, Lotte ; Engelholm, Svend A ; Petri, Anette L ; Risum, Signe ; Lundvall, Lene ; Yip, Christine ; Pedersen, Anette T ; Hartwell, Dorthe ; Lomas, Lee ; Høgdall, Estrid V S. / A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. In: Gynecologic Oncology. 2011 ; Vol. 123, No. 2. pp. 308-13.
Bibtex
@article{cf22dde7f10445d4b9d24229a5c1bd91,
title = "A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer",
abstract = "Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.",
author = "Claus H{\o}gdall and Fung, {Eric T} and Christensen, {Ib J} and Lotte Nedergaard and Engelholm, {Svend A} and Petri, {Anette L} and Signe Risum and Lene Lundvall and Christine Yip and Pedersen, {Anette T} and Dorthe Hartwell and Lee Lomas and H{\o}gdall, {Estrid V S}",
note = "Copyright {\textcopyright} 2011 Elsevier Inc. All rights reserved.",
year = "2011",
doi = "http://dx.doi.org/10.1016/j.ygyno.2011.07.018",
language = "English",
volume = "123",
pages = "308--13",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "2",
}
RIS
TY - JOUR
T1 - A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer
AU - Høgdall, Claus
AU - Fung, Eric T
AU - Christensen, Ib J
AU - Nedergaard, Lotte
AU - Engelholm, Svend A
AU - Petri, Anette L
AU - Risum, Signe
AU - Lundvall, Lene
AU - Yip, Christine
AU - Pedersen, Anette T
AU - Hartwell, Dorthe
AU - Lomas, Lee
AU - Høgdall, Estrid V S
N1 - Copyright © 2011 Elsevier Inc. All rights reserved.
PY - 2011
Y1 - 2011
N2 - Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
AB - Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
U2 - http://dx.doi.org/10.1016/j.ygyno.2011.07.018
DO - http://dx.doi.org/10.1016/j.ygyno.2011.07.018
M3 - Journal article
VL - 123
SP - 308
EP - 313
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 2
ER -
